<DOC>
	<DOCNO>NCT00804908</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ABT-888 combination temozolomide versus temozolomide alone subject metastatic melanoma .</brief_summary>
	<brief_title>A Study Evaluating Efficacy ABT-888 Combination With Temozolomide Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically ( cytologically ) confirm metastatic melanoma . Unresectable Stage III Stage IV metastatic melanoma . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Subjects history brain metastasis demonstrate baseline MRI , subject history previously treat brain metastasis history operable/SRS treatable brain metastasis complete surgical resection/stereotactic radiosurgery without adjuvant whole brain radiation least 28 day prior Day 1 ; baseline MRI show evidence active intercranial disease ; discontinue take medication symptom management brain metastasis least 7 day prior Day 1 28 day since prior anticancer therapy . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 . Adequate hematologic , renal hepatic function . Partial Thromboplastin Time ( PTT ) &lt; = 1.5 x upper normal limit institution 's normal range international normalize ratio ( INR ) &lt; 1.5 . Subject 's significant fluid retention may allow discretion investigator . Life expectancy &gt; 12 week . Females must pregnant . Voluntarily sign informed consent . Lactate Dehydrogenase ( LDH ) &gt; 2 x Upper Limit Normal ( ULN ) . Ocular malignant melanoma . History central nervous system metastases leptomeningeal disease . Prior treatment Dacarbazine ( DTIC ) Temozolomide ( TMZ ) . Prior DNA damage agent cytotoxic chemotherapy . Prior Whole Brain Radiation Therapy ( exception ) . Received investigational agent within 28 day study . History seizure disorder and/or take medication seizure disorder . Active malignancy within past 5 year , except cervical cancer situ , situ carcinoma bladder nonmelanoma carcinoma skin . Medical condition would cause high risk toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Temozolomide</keyword>
	<keyword>Skin cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>ABT-888</keyword>
	<keyword>MM</keyword>
</DOC>